The Life Sciences company is taking decisive action to address the challenge posed by Antimicrobial Resistance
Arcera Life Sciences, a global life sciences company headquartered in Abu Dhabi, recently announced the signing of a strategic MoU with ISPOR UAE Chapter to advance healthcare innovation in the UAE and the launch of a breakthrough intravenous antibiotic to combat Antimicrobial Resistance (AMR).
This is a major milestone in Arcera’s mission to enable patient access to innovative therapies and improve healthcare outcomes.
Antimicrobial Resistance (AMR) is classified by the World Health Organization as a top global public health threat; n 2021 alone, an estimated 1.14mn deaths were directly attributed to bacterial AMR.
Decisive action
Arcera is taking decisive action to address the challenge posed by AMR. The company is introducing a breakthrough intravenous antibiotic that restores efficacy against multidrug-resistant bacteria, including Extended Spectrum Beta-Lactamase (ESBL)-producing pathogens, offering physicians a new treatment option.
To advance its mission of enabling access to such innovative therapies, Arcera has signed a strategic MoU with ISPOR UAE Chapter, the leading professional society for health economics and outcomes research globally, at the ISPOR UAE Chapter 2026 Conference.
Healthcare investment
“Together, we aim to strengthen decision-making, support sustainable healthcare investment, and ensure that patients receive timely access to advanced treatments,” stated Isabel Afonso, Chief Executive Officer, Arcera Life Sciences.
“The UAE is a rapidly evolving market for health technology, and by combining ISPOR UAE Chapter’s global network and resources with Arcera’s regional leadership, we can more effectively address the unique challenges of this landscape and promote excellence in research and policy,” explained Prof. Nadia AL Mazrouei, ISPOR UAE Chapter President.
